Ganitumab

Drug Profile

Ganitumab

Alternative Names: AMG-479

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Millennium; National Cancer Institute (USA); Takeda; Takeda Oncology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ewing's sarcoma; Solid tumours
  • No development reported Breast cancer; Colorectal cancer; Sarcoma; Small cell lung cancer
  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Japan (IV, Injection)
  • 15 Mar 2016 Biomarkers information updated
  • 22 Jan 2016 Dyax has been acquired by and merged into Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top